BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STOBOCLO (denosumab-bmwo) by Celltrion is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STOBOCLO is a monoclonal antibody biosimilar to denosumab (PROLIA/XGEVA) that blocks RANK ligand, a key mediator of bone resorption and immune cell activation. It is indicated for osteoporosis, bone metastases, and giant cell tumor of bone. The drug works by inhibiting osteoclast formation and function, reducing bone loss and skeletal-related events.
Growth
Early-stage biosimilar entry into a maturing RANK ligand market; team will focus on rapid market penetration and payer contracting against established reference products.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Celltrion is hiring 1 role related to this product
Worked on STOBOCLO at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.